top of page
Search


The national insurers' financial performance in Q3 2025: MLRs continue to worsen even as overall performance is relatively strong
Over the past few weeks, all five national, publicly traded health plans have hosted their third set of earnings calls for the year, sharing their performance from Q3 and their outlook for the remainder of 2025. We make it a point to stay on top of these players’ performance to monitor the health insurance industry’s overall financial position and to see what the data tell us about ongoing demographic shifts, the margin outlook for providers, the real-world/cost implications

Jordan Peterson
20 hours ago12 min read


Agentic AI in healthcare in 2025: Separating the near-term use cases from the hype
Agentic AI in healthcare has rapidly become the centerpiece of health tech discussions. We’ve been studying it because it’s an area of rapid growth and advancement—an outlier in this moment in healthcare, when stakeholders across the industry are struggling amidst rising expenses, workforce shortages, and patient experience frustrations. Agentic AI tools are being positioned as a game-changing approach to addressing many of the industry’s biggest challenges, given their state

Marina Renton
Nov 78 min read


Down on the Upside? Unpacking the current state of vertical consolidation
For years, vertical consolidation has been a mainstay of the insurer playbook—blending payer, provider, pharmacy, and PBM assets into a single, integrated ecosystem designed to drive synergies, provide consistent margin performance, and withstand turbulence to any one part of the business. It’s a strategy that worked remarkably well through the 2010s and early 2020s. We may be reaching a turning point. Recent financial results across all national players —but especially from

Jordan Peterson
Oct 3011 min read


What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care
Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s). Originally developed for diabetes management, these drugs, popularized under brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound, are redefining how we think about obesity, metabolic health, and even chronic disease prevention. And increasingly, GLP-1s are no longer just about controlling blood sugar. They have become c

Brandon Aylward
Oct 1610 min read


Revisiting an under-the-radar quality program: Should hospitals take another look at the Patient Safety Organization (PSO) program?
With a new federal measure set to reward hospitals for participating in the Agency for Healthcare Research and Quality's (AHRQ) Patient Safety Organization (PSO) program starting next year—and a fresh government evaluation pushing for tweaks to the program to improve its effectiveness—PSOs have quickly moved from a relatively niche quality program to a potential strategy priority. PSOs play a strategic role by offering legal protections for safety event data and positioning o

Marina Renton
Oct 1011 min read


Are ICHRAs the next 401(k)s? Current trends in employer spending and employer adoption of ICHRAs
Healthcare costs are accelerating faster than anyone predicted, and employers are struggling to keep up. And our team has been having an internal debate about a scenario that seemed unlikely even just a few years ago: could employer-sponsored insurance (ESI) finally be approaching its defined contribution moment—echoing the pension-to-401(k) transition that reshaped retirement benefits a generation ago? Employers have long relied on ESI to attract and retain workers, but risi

Jordan Peterson
Oct 112 min read


Examining MAHA’s jump into Real World Data (RWD), and what other industry players can learn from it
MAHA's recent strategic plan announced its intent to create a comprehensive real-world data asset to fuel research. However, any desire to move from data source to insight is likely to be more complex than merely acquiring some data. What potential pitfalls could lie ahead and what can other organizations learn from this?

Eric Fontana
Sep 2418 min read


Different players, different games: How healthcare’s various sectors are using AI differently in 2025
All U.S. health systems, hospitals, provider groups, life sciences organizations, and national or regional payers are racing to scale AI....

Chris Loumeau
Sep 129 min read


What's on the MAHA agenda as of mid-2025: Where it's focused, and what it means for the healthcare industry
When we last wrote about “Make America Healthy Again” (MAHA) earlier this year, the initiative was more of a slogan than a...

Brandon Aylward
Sep 514 min read


The state of rural hospitals in 2025: In survival mode against a backdrop of rising expenses and political uncertainty
For the better part of the last decade, rural hospitals have been running on thin ice. In 2025, that ice appears poised to splinter. Core...

Jordan Peterson
Aug 1910 min read


The national insurers' financial performance in Q2 2025: A tale of two (types of) payers
Over the course of the past few weeks, all five of the large, publicly traded health plans have hosted their second set of earnings calls...

Jordan Peterson
Aug 1812 min read


Hospital revenue cycle trends to watch in 2025-2026: Key takeaways from our Provider RCM Summit
Last week, Union Healthcare Insight had the privilege of gathering with an impressive group of hospital revenue cycle executives in...

Eric Fontana
Aug 146 min read
Join our mailing list
Get access to our latest posts
bottom of page
